Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Capital Expenditures (2021 - 2025)

PAVmed has reported Capital Expenditures over the past 5 years, most recently at $14000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $14000.0 for Q4 2025, up 250.0% from a year ago — trailing twelve months through Dec 2025 was $31000.0 (down 86.64% YoY), and the annual figure for FY2025 was $31000.0, down 43.64%.
  • Capital Expenditures for Q4 2025 was $14000.0 at PAVmed, up from $3000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for PAVM hit a ceiling of $1.3 million in Q4 2021 and a floor of $3000.0 in Q2 2024.
  • Median Capital Expenditures over the past 5 years was $35000.0 (2021), compared with a mean of $175315.8.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 1494.44% in 2022 and later tumbled 97.81% in 2024.
  • PAVmed's Capital Expenditures stood at $1.3 million in 2021, then tumbled by 76.66% to $298000.0 in 2022, then tumbled by 38.59% to $183000.0 in 2023, then tumbled by 97.81% to $4000.0 in 2024, then soared by 250.0% to $14000.0 in 2025.
  • The last three reported values for Capital Expenditures were $14000.0 (Q4 2025), $3000.0 (Q3 2025), and $8000.0 (Q2 2025) per Business Quant data.